Generic Medicine Info
Indications and Dosage
Adult: 60-150 mg daily.
Child: IM: >2½ yr: 200-250 mcg/kg daily. Max: 10mg daily.
Elderly: or debilitated patients: Dose reduction is recommended.

Nausea and vomiting
Adult: IV: 1 mg/dose; max: 3 mg daily. IM: 5-15 mg, repeated after 4 hr if necessary; max: 60 mg daily.
Child: IM: >2½ yr: 200-250 mcg/kg daily. Max: 10mg daily.
Elderly: or debilitated patients: Dose reduction is recommended.
Preexisting CNS depression and coma; bone marrow depression, blood dyscrasias, liver disease, hypersensitivity to phenothiazines, prolactin dependent tumours. Pregnancy (1st trimester), lactation.
Special Precautions
Cardiovascular disease, epilepsy, angle-closure glaucoma, exposure to extreme temperatures, parkinson's disease, myasthenia gravis, benign prostatic hyperplasia, DM, renal amd hepatic impairment. Discontinue triflupromazine at least 48 hr before myelography and do not resume for at least 24 hr after procedure. Do not use in control of nausea and vomiting occurring either prior to myelography or postprocedure with metrizamide. Pregnancy, elderly.
Adverse Reactions
Blurred vision, dry mouth, urinary hesitancy/retention, constipation, orthostatic hypotension, allergic rash, akathisia, dystonias, muscle weakness, anorexia, insomnia.
Potentially Fatal: Blood dyscrasias, malignant neuroleptic syndrome.
Drug Interactions
Increased CNS depression with CNS depressants such as opiates or other analgesics, barbiturates or other sedatives, general anaesthetics, or alcohol. Increased risk of side effects with drugs with antimuscarinic properties e.g. TCA, antiparkinsonian drugs. Antagonised effects of dopaminergic drugs such as levodopa. Increased risk of hypotension with antihypertensives, trazodone. Reverses antihypertensive effect of guanethidine. Increased risk of severe extrapyramidal side-effects or severe neurotoxicity with lithium. Possible decrease in absorption with antacids.
Description: Triflupromazine is a phenothiazine with general properties similar with chlorpromazine.
MIMS Class
Antiemetics / Antipsychotics
Disclaimer: This information is independently developed by MIMS based on Triflupromazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in